Bio-Techne’s Ella immunoassay platform has received CE-IVD marking, enabling its sale and use in the European Union for clinical laboratories. This compact, cartridge-based system provides rapid, reproducible biomarker results in under 90 minutes. The certification allows hospitals and labs to use Ella for in-house test development, clinical trials, and other translational activities, enhancing precision diagnostics.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Bio-Techne's Ella Platform Achieves CE-IVD Marking Expanding Access to Rapid, Cartridge‑Based Immunoassays for European Clinical Laboratories
Bio-Techne’s Ella immunoassay platform has received CE-IVD marking, enabling its sale and use in the European Union for clinical laboratories. This compact, cartridge-based system provides rapid, reproducible biomarker results in under 90 minutes. The certification allows hospitals and labs to use Ella for in-house test development, clinical trials, and other translational activities, enhancing precision diagnostics.